Early combo diabetes drugs may cut death risk in obese patients
NCT ID NCT07465926
First seen Mar 16, 2026 · Last updated May 12, 2026 · Updated 7 times
Summary
This study used health records from over 450,000 adults with obesity and type 2 diabetes to see if adding a second medication early (like GLP-1 or SGLT2 drugs) improves survival and kidney health. Researchers compared those who added another drug within 90 days to those who did not. The goal was to understand which treatment strategies work best for preventing death and serious heart or kidney problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.